Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
34°
Rain Shower
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
92.13
-1.26 (-1.35%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...
Via
Benzinga
Biotech Stocks Poised For Another Big Move In Q4
October 07, 2024
The healthcare sector can be a safe haven if volatility increases.
Via
Talk Markets
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
October 07, 2024
Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
October 07, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
October 04, 2024
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
October 01, 2024
Via
Benzinga
News Is Noise
September 23, 2024
Via
Talk Markets
Top 4 Health Care Stocks That May Keep You Up At Night
September 24, 2024
Via
Benzinga
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
September 23, 2024
Gilead Sciences has recalled one lot of its COVID-19 treatment, Veklury (remdesivir), due to glass particles found in vials. Gilead is notifying distributors to cease use and return the remaining...
Via
Benzinga
Topics
Product Recall
Exposures
COVID-19
Legal
Product Safety
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
September 23, 2024
The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment.
Via
Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
September 21, 2024
Bargain hunters should love these great stocks.
Via
The Motley Fool
Gilead Sciences Unusual Options Activity For September 20
September 20, 2024
Via
Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
September 20, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
September 13, 2024
Via
Benzinga
What the Options Market Tells Us About Gilead Sciences
September 12, 2024
Via
Benzinga
Peering Into Gilead Sciences's Recent Short Interest
September 06, 2024
Via
Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
September 14, 2024
These two stocks have had their issues in recent years, but both look like reliable long-term bets.
Via
The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Why Gilead Sciences Stock Thrashed the Market Today
September 12, 2024
In drug development, solid performance in large-scale clinical trials is crucial.
Via
The Motley Fool
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
September 12, 2024
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by...
Via
Benzinga
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
September 12, 2024
The company is trying to get ahead of a patent expiration for one of its key HIV prevention drugs.
Via
Investor's Business Daily
Topics
Intellectual Property
Exposures
Intellectual Property
Unveiling 10 Analyst Insights On Gilead Sciences
September 04, 2024
Via
Benzinga
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
September 03, 2024
Via
Benzinga
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
August 27, 2024
Via
Benzinga
Four Stocks To Watch This Week - Monday, Sept 9
September 09, 2024
Inconsistent patchy behavior looks most likely in the very short term, but stocks still have decent potential in the medium term. Stay focused and be patient for the optimal setups near Key Levels.
Via
Talk Markets
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
September 03, 2024
Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging technical signals.
Via
Benzinga
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good.
Via
Talk Markets
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
August 26, 2024
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process.
Via
Investor's Business Daily
Exposures
Product Safety
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
August 22, 2024
Via
Benzinga
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.